LWM
BCRX icon

Lyons Wealth Management’s BioCryst Pharmaceuticals BCRX Stock Holding History

Lyons Wealth Management’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-11,000
Closed -$84K – 67
2013
Q4 		$84K Buy
11,000
+1,000
+10% +$6.33K 0.08% 57
2013
Q3 		$73K Hold
10,000
– – 0.07% 67
2013
Q2 		$16K Buy
+10,000
New +$17.3K 0.02% 77

Other funds holding BCRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VM
VHCP Management New York $93M AUM 10.04% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Lyons Wealth Management's BCRX Position: Q1 2014 in Review

Lyons Wealth Management sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2014, closing a stake of 11,000 shares — an estimated $84K sold.

Lyons Wealth Management first reported a position in BCRX in Q2 2013 and held it in 3 quarters. The position peaked at $84K in Q4 2013. 88 funds tracked by Wall St. Rank hold BCRX as of Q1 2014.

  • Lyons Wealth Management reported no remaining BioCryst Pharmaceuticals position as of Q1 2014 after selling out during the quarter.
  • Lyons Wealth Management sold 11,000 BioCryst Pharmaceuticals shares in Q1 2014, an estimated $84K.
  • Lyons Wealth Management first reported a position in BioCryst Pharmaceuticals in Q2 2013 and held it in 3 quarters.
  • Lyons Wealth Management's BioCryst Pharmaceuticals position peaked at $84K in Q4 2013.
  • 88 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2014.

Based on Lyons Wealth Management's 13F filing for Q1 2014, filed 14 May 2014.